2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support

2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support

Bradycardia is defined electrophysiologically as a heart rate $<50\text{ bpm}$ in adults. However, clinical management in the emergency setting is dictated by the presence or absence of end-organ hypoperfusion rather than an isolated numeric cutoff. When cardiac output declines secondary to inadequate chronotropy, the emergency medicine pharmacist must guide rapid pharmacologic escalation, recognize anatomical and pharmacodynamic limitations of first-line agents, prepare vasoactive infusions, and address toxicologic and ischemic drivers.

---

Identification of Hemodynamically Unstable Bradycardia

Patients presenting with bradycardia fall into two clinical categories:

1. Asymptomatic / Stable Bradycardia: The patient maintains adequate perfusion without signs of shock or ischemia. Management focuses on obtaining a 12-lead ECG, establishing continuous cardiac telemetry, and evaluating for reversible underlying causes (e.g., athletic conditioning, hypothyroidism, obstructive jaundice, or baseline nodal medications). Routine pharmacotherapy is not indicated.
2. Symptomatic / Unstable Bradycardia: The bradycardia is directly producing signs or symptoms of systemic hypoperfusion:
   • Hypotension: Systolic BP $<90\text{ mmHg}$ or MAP $<65\text{ mmHg}$.
   • Acutely Altered Mental Status: Lethargy, confusion, syncope, or presyncope.
   • Signs of Shock: Diaphoresis, cyanosis, delayed capillary refill, cool extremities.
   • Ischemic Chest Discomfort: Angina or ischemic ECG changes driven by low coronary perfusion.
   • Acute Decompensated Heart Failure: Pulmonary edema or severe orthopnea.

Unstable patients require immediate resuscitation following the ACLS bradycardia algorithm.

---

First-Line Pharmacotherapy: Atropine Sulfate

Atropine is a competitive antagonist at postganglionic muscarinic acetylcholine receptors (predominantly $M_2$ receptors in cardiac tissue). By blocking vagal parasympathetic input to the sinoatrial (SA) and atrioventricular (AV) nodes, atropine abolishes vagal inhibitory tone, accelerates SA nodal automaticity, and shortens AV nodal conduction time.

Dosing and Administration Protocol

• Dose: 1 mg IV push administered rapidly, repeated every 3 to 5 minutes as needed.
• Maximum Cumulative Dose: 3 mg (which achieves complete vagal blockade in adult humans; doses beyond 3 mg provide no additional parasympathetic antagonism).
• The 1 mg Starting Dose Rationale: Historical guidelines recommended 0.5 mg boluses. The ACLS update established 1 mg as the minimum initial dose because subtherapeutic doses ($<0.5\text{ mg}$) or slow IV administration block presynaptic inhibitory $M_1$ autoreceptors on parasympathetic nerve endings. This presynaptic blockade promotes paradoxical acetylcholine release before postsynaptic $M_2$ blockade occurs, triggering paradoxical bradycardia or transient high-grade AV block.

Anatomic and Pharmacologic Limitations: When Atropine Fails

Atropine is not universally effective. Emergency medicine pharmacists must identify clinical scenarios where atropine will fail, avoiding dangerous resuscitation delays:

1. Infranodal AV Conduction Disease: Atropine accelerates conduction through the AV node, but has zero effect on tissue below the AV node (His bundle and bundle branches), which lacks vagal parasympathetic innervation.
   • Mobitz Type II Second-Degree AV Block: Block is located in the His-Purkinje system. Atropine will increase the sinus rate without improving infranodal conduction, frequently increasing the ratio of non-conducted P waves and worsening bradycardia.
   • Third-Degree (Complete) AV Block with Wide QRS: The ventricular escape pacemaker originates in infranodal ventricular tissue lacking vagal innervation. Atropine will not accelerate the ventricular rate.
2. Orthotopic Heart Transplantation: The donor heart is completely surgically denervated during transplantation, severing all autonomic vagal connections. Atropine produces zero chronotropic response.
3. Acute Myocardial Infarction: In acute coronary ischemia, excessive atropine-induced tachycardia markedly accelerates myocardial oxygen demand ($MVO_2$), potentially extending myocardial infarction size or precipitating ventricular tachydysrhythmias.

---

Second-Line Chronotropic Vasoactive Infusions

When atropine fails, is contraindicated, or while preparing for transcutaneous or transvenous pacing, continuous chronotropic infusions provide reliable hemodynamic and rate support:

Loading diagram...

1. Epinephrine Infusion

• Mechanism: Direct, potent alpha-1, beta-1, and beta-2 adrenergic agonist. Beta-1 activation stimulates SA nodal automaticity and AV nodal conduction velocity, while alpha-1 vasoconstriction elevates blood pressure and coronary perfusion.
• ACLS Dosing: 2 to 10 mcg/min continuous IV infusion (non-weight-based in adult ACLS), titrated to target heart rate ($>50\text{ to }60\text{ bpm}$) and resolution of hypoperfusion.
• Push-Dose Epinephrine as a Bridge: While waiting for an infusion pump, prepare push-dose epinephrine ($10\text{ mcg/mL}$ concentration: dilute 1 mL of 0.1 mg/mL cardiac arrest epinephrine into 9 mL of 0.9% NaCl). Administer 10 to 20 mcg (1 to 2 mL) IV every 2 to 5 minutes as a rapid temporizing bridge.

2. Dopamine Infusion

• Mechanism: Endogenous catecholamine precursor. At chronotropic infusion rates ($5\text{ to }20\text{ mcg/kg/min}$), it primarily stimulates beta-1 adrenergic receptors, enhancing chronotropy and inotropy. At higher doses ($>10\text{ to }20\text{ mcg/kg/min}$), alpha-1 mediated vasoconstriction becomes prominent.
• ACLS Dosing: 5 to 20 mcg/kg/min continuous IV infusion, starting at 5 mcg/kg/min and titrating by 2.5 to 5 mcg/kg/min every 5 to 10 minutes.
• Safety Note: Dopamine is a potent vesicant. Central line infusion is strongly preferred. If peripheral extravasation occurs, immediately infiltrate phentolamine (5 to 10 mg diluted in 10 mL saline) locally to prevent ischemic tissue necrosis.

3. Isoproterenol Infusion

• Mechanism: Pure non-selective beta-1 and beta-2 adrenergic agonist with zero alpha-1 activity.
• Dosing: 2 to 10 mcg/min continuous IV infusion, titrated to heart rate response.
• Clinical Utility: Ideal in orthotopic heart transplant recipients (denervated myocardium retains intact beta receptors) and in bradycardia-dependent polymorphic VT / Torsades de Pointes where accelerating heart rate shortens the QT interval. It causes peripheral vasodilation (beta-2 effect) and must be used with caution in hypotensive shock.

---

Chronotropic Infusion Comparison Matrix

---

Transcutaneous Pacing (TCP) & Analgesia

Transcutaneous pacing should be initiated immediately in patients with unstable high-grade AV block or when atropine fails. The steps for proper electrical and mechanical capture include:

1. Pad Placement: Anterior-posterior pad positioning provides lower pacing thresholds than anterolateral placement.
2. Rate & Current Titration: Set rate to 60 to 80 ppm. Begin at 0 mA and increase current until electrical capture is demonstrated (a distinct pacer spike immediately followed by a wide QRS complex and broad T wave).
3. Verification of Mechanical Capture: Palpate the femoral or right radial pulse, or observe a pulsatile arterial line waveform corresponding to each pacer spike. Never palpate the carotid pulse (muscular twitching of the neck mimics a pulse).
4. Analgesia & Sedation: Transcutaneous electrical capture causes painful skeletal muscle contractions. Administer IV fentanyl (25 to 50 mcg) and/or IV midazolam (1 to 2 mg) in conscious patients.

---

Special Etiologies and Antidotal Resuscitation

1. Beta-Blocker and Calcium Channel Blocker Toxicity

Overdoses of beta-blockers or non-dihydropyridine calcium channel blockers trigger refractory bradycardia, cardiogenic shock, and AV nodal arrest unresponsive to atropine.

• High-Dose Insulin Euglycemia Therapy (HIET): Increases myocardial glucose uptake, restores carbohydrate oxidation in shocked myocytes, and provides potent positive inotropic and chronotropic effects.
  • Bolus: Regular insulin 1 unit/kg IV bolus.
  • Continuous Infusion: Regular insulin 0.5 to 1 unit/kg/hour, titrating up to 2 to 10 units/kg/hour in refractory shock.
  • Dextrose Support: Co-infuse 10% or 50% dextrose (titrated to maintain euglycemia between 100 and 180 mg/dL), monitoring blood glucose every 15 to 30 minutes initially.
  • Potassium Monitoring: Insulin drives potassium intracellularly; supplement potassium to keep serum levels $3.0\text{ to }3.5\text{ mEq/L}$.
• Calcium Chloride 10%: 1 to 2 g IV over 5 to 10 minutes, repeated every 15 to 20 minutes (up to 3 to 4 doses) or given as a continuous infusion (0.2 to 0.4 mL/kg/h) to overcome competitive L-type channel blockade.
• Glucagon: 3.5 to 5 mg (50 to 150 mcg/kg) IV bolus over 3 to 5 minutes, followed by an infusion matching the effective bolus dose per hour. Glucagon bypasses adrenergic receptors to stimulate adenylate cyclase, increasing intracellular cAMP.

2. Hyperkalemia-Induced Conduction Blocks

Severe hyperkalemia ($K^+ > 6.5\text{ to }7.0\text{ mEq/L}$) decreases resting membrane potential, leading to sinus arrest, nodal escape rhythms, and sinusoidal QRS widening.

• Immediate Intervention: Calcium chloride 1 g IV push over 2 to 5 minutes to restore the threshold potential and stabilize cardiac membranes.

3. Inferior Wall Myocardial Infarction

The right coronary artery (RCA) supplies the sinoatrial node in 60% of patients and the atrioventricular node in 90% (via the AV nodal artery). Inferior STEMI commonly produces severe vagally mediated sinus bradycardia or first/second-degree AV block via the Bezold-Jarisch reflex. This reflex usually responds well to atropine. However, if right ventricular infarction is present (elevated JVD with clear lungs), the patient is preload-dependent; avoid nitrates and volume-depleting agents.